Trial shows success in treating drug-resistant TB
A 26-week treatment of 109 XDR-TB and MDR-TB patients with three oral drugs — bedaquiline, pretomanid, and linezolid — showed 90% success rate. There were seven deaths and two had…
A Science and Technology Blog
A 26-week treatment of 109 XDR-TB and MDR-TB patients with three oral drugs — bedaquiline, pretomanid, and linezolid — showed 90% success rate. There were seven deaths and two had…
Though the total number of people with XDR-TB and treatment intolerant or non-responsive MDR-TB who will require the new anti-TB drug Pretomanid may not be high, these are people who…
When used in combination with bedaquiline and linezolid, the newly approved pretomanid drug for MDR-TB and XDR-TB had an overall treatment success rate of about 90%. Besides better effectiveness, the…
While India has set a highly ambitious target of “eliminating TB by 2025”, modelling studies published today say incidence and mortality will reduce by just 57% and 72% respectively by…
A team of researchers from three institutions in India has used aptamer-based inhibitor that binds to the HupB protein found on TB bacteria cell surface to significantly inhibit the entry…
In a “rapid communication”, WHO has informed all member States to take “immediate steps” to ensure that all injectables are replaced with a fully-oral regimen that includes bedaquiline to treat…
In a Phase III trial, delamanid drug was found to be safe but the cure rate and mortality rate were not different between the group that received the delamanid drug…
There is a glimmer of hope with India registering a slight drop in the number of new tuberculosis cases and TB deaths in 2016 compared with 2015. From an estimated…